Shenzhen TargetRx, Inc.
Shenzhen TargetRx develops targeted small-molecule anticancer therapies that address acquired drug resistance and unmet clinical needs. The company uses structure-based design, artificial intelligence-driven screening, and medicinal chemistry to design and optimize next-generation small molecules, including a pipeline of BCR-ABL inhibitors. Shenzhen TargetRx is an R&D-focused biopharmaceutical company working with healthcare institutions and oncology researchers to advance candidate therapies through preclinical development. The team is led by founder Dr. Yihan Wang, an experienced small-molecule drug inventor with multiple patents and clinical-stage program experience. The company is positioned in the precision medicine oncology market aiming to translate its candidates into clinical solutions for resistant cancers.
Shenzhen TargetRx, Inc.
Shenzhen TargetRx develops targeted small-molecule anticancer therapies that address acquired drug resistance and unmet clinical needs. The company uses structure-based design, artificial intelligence-driven screening, and medicinal chemistry to design and optimize next-generation small molecules, including a pipeline of BCR-ABL inhibitors. Shenzhen TargetRx is an R&D-focused biopharmaceutical company working with healthcare institutions and oncology researchers to advance candidate therapies through preclinical development. The team is led by founder Dr. Yihan Wang, an experienced small-molecule drug inventor with multiple patents and clinical-stage program experience. The company is positioned in the precision medicine oncology market aiming to translate its candidates into clinical solutions for resistant cancers.